First Nicotine Pouch MRTP: How ZYN’s 10 Flavors Achieved FDA Reduced‑Exposure Status

For biopharmaceutical and regulatory affairs professionals, the ZYN MRTP order is a case study in how to navigate the FDA’s stringent modified risk pathway for a non‑combustible nicotine product. It demonstrates the type of biomarker data, clinical bridging, and post‑market commitment required to secure an exposure reduction claim—offering a potential template for next‑generation nicotine delivery.

In a landmark regulatory decision, the U.S. Food and Drug Administration authorized the first-ever modified risk tobacco product (MRTP) orders for nicotine pouches, granting Philip Morris International permission to market ten ZYN varieties with claims that they reduce exposure to harmful chemicals compared to cigarettes. The July 1, 2026 orders cover the Cool Mint, Peppermint, Spearmint, Wintergreen, Citrus, Coffee, Cinnamon, Smooth, Chill, and Menthol flavors. This milestone, more than a decade into the MRTP pathway, signals a significant evolution in tobacco regulation and harm-reduction product oversight.

“

Philip Morris, which acquired ZYN's parent Swedish Match in 2022, has staked its future on smoke‑free products, aiming for over 50% of net revenues from smoke‑free products by 2025.

The MRTP framework, established by the 2009 Family Smoking Prevention and Tobacco Control Act, allows manufacturers to seek FDA authorization to market a tobacco product as reducing harm or exposure to harmful substances. However, the bar has been extremely high. Prior to ZYN, the only product to receive any MRTP order was Philip Morris's IQOS heated tobacco system, first authorized for "exposure reduction" claims in July 2020. The ZYN orders are likewise exposure reduction orders—a distinction from "risk modification" orders, which would require evidence that the product actually reduces disease or death. The FDA explicitly stated these orders do not mean the products are safe or "FDA approved," and all tobacco products carry risk, including nicotine addiction.

The authorization permits Philip Morris to communicate that switching completely from cigarettes to ZYN significantly reduces exposure to the harmful and potentially harmful constituents (HPHCs) linked to smoking-related diseases. This claim is supported by scientific evidence the company submitted, including data showing that adult smokers who exclusively use ZYN have substantially lower levels of biomarkers of exposure to HPHCs compared to those who continue smoking. The FDA's decision also imposes strict postmarket surveillance requirements, obligating the company to monitor youth appeal, unintended use, and long-term health impacts in real-world settings.

The market implications are substantial. Nicotine pouches have been one of the fastest-growing segments in the U.S. tobacco space, with ZYN capturing a dominant share. Before the authorization, oral nicotine products could only be marketed without health‑related claims; the ability to now communicate a reduced‑exposure message to adult smokers could accelerate the shift from combustible cigarettes, representing a multi‑billion‑dollar opportunity. Philip Morris, which acquired ZYN's parent Swedish Match in 2022, has staked its future on smoke‑free products, aiming for over 50% of net revenues from smoke‑free products by 2025. The MRTP orders validate that strategy and give ZYN a competitive moat that rivals—such as British American Tobacco's Velo or Altria's on!—don't yet possess.